Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics’ Pipeline of Next-Generation Gene Therapies to the Clinic
Partnership will include cGMP manufacturing services for AFTX-201, Affinia's investigational gene therapy medicine for BAG3 dilated cardiomyopathy